solute carrier family 39 member 5Genealiases: LZT-Hs7 · MYP24 · ZIP5
Q-omics provides the consensus-scored SLC39A5 profile across patient tissues and cancer cell-line models. SLC39A5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC39A5 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SLC39A5 RNA expression shows 16,622 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where SLC39A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC39A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC39A5 survival associations across molecular data types. SLC39A5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC39A5 RNA expression–survival associations across cancer types. High SLC39A5 expression shows unfavorable associations in ACC, UCEC and MESO, but favorable associations in KIRC, KIRP and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC39A5 RNA expression.
This table summarizes SLC39A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC39A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC39A5 shows lower tumor expression in KICH, COAD, LIHC, CHOL and KIRP and higher tumor expression in HNSC. The KICH box plot shows higher SLC39A5 RNA expression in normal versus tumor tissue (log2 FC = −5.072, t-test p < 0.001).
This table shows molecular features associated with SLC39A5 in patient tissues and cancer cell lines. In patient samples, SLC39A5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC39A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
